Disease, patient, and transplantation characteristics and univariate analysis of factors affecting survival of 129 patients with engraftment
Variable (no. of patients available) . | Dead/no. . | P by log-rank . | Univariate RR . |
|---|---|---|---|
| Severity of the disease at diagnosis (105) | |||
| Nonsevere | 10/25 | .23 | 2.58 |
| Severe | 22/80 | 1 | |
| Infection within 3 mo before transplantation | |||
| No | 25/87 | 1 | |
| Yes | 17/42 | .15 | 1.56 |
| Specific treatment before transplantation | |||
| No | 17/66 | .03 | 1 |
| Yes | 25/63 | 1.94 | |
| ATG (n = 63; previous treatment) | |||
| No | 10/33 | .21 | 1 |
| Yes | 15/30 | 1.65 | |
| CsA (n = 63; previous treatment) | |||
| No | 22/47 | .07 | 2.84 |
| Yes | 3/16 | 1 | |
| Androgens (n = 63; previous treatment) | |||
| No | 9/25 | .56 | 1 |
| Yes | 16/38 | 1.27 | |
| Recipient sex | |||
| Male | 29/79 | .14 | 1 |
| Female | 13/50 | 1.63 | |
| Donor sex (128) | |||
| Male | 20/70 | .09 | 1 |
| Female | 22/58 | 1.50 | |
| Patient age, y | |||
| Younger than 15 | 11/49 | .04 | 1 |
| 15 or older | 31/80 | 2.04 | |
| Younger than 15 | 11/49 | .17 | 1 |
| 15-20 | 8/22 | 1.85 | |
| 20-30 | 12/34 | 1.87 | |
| Older than 30 years | 11/24 | 2.47 | |
| Patient CMV serologic status (105) | |||
| Negative | 15/43 | .70 | 1.15 |
| Positive | 16/62 | 1 | |
| Major ABO incompatibility | .57 | ||
| No | 38/119 | 1 | |
| Yes | 4/10 | 1.34 | |
| Transfusions before transplantation (109) | |||
| Fewer than 20 | 18/63 | .13 | 1 |
| 20 or more | 18/46 | 1.66 | |
| Interval before transplantation (128) | |||
| Less than a year | 29/107 | .001 | 1 |
| More than a year | 12/21 | 2.96 | |
| Conditioning regimen | |||
| Cy-ATG | 2/31 | .006 | 1 |
| Cy-TAI | 40/98 | 5.81 | |
| GvHD prophylaxis regimen | |||
| MTX alone | 6/16 | .13 | 1 |
| CsA alone | 21/46 | 1.24 | |
| CsA + MTX | 15/67 | 0.64 |
Variable (no. of patients available) . | Dead/no. . | P by log-rank . | Univariate RR . |
|---|---|---|---|
| Severity of the disease at diagnosis (105) | |||
| Nonsevere | 10/25 | .23 | 2.58 |
| Severe | 22/80 | 1 | |
| Infection within 3 mo before transplantation | |||
| No | 25/87 | 1 | |
| Yes | 17/42 | .15 | 1.56 |
| Specific treatment before transplantation | |||
| No | 17/66 | .03 | 1 |
| Yes | 25/63 | 1.94 | |
| ATG (n = 63; previous treatment) | |||
| No | 10/33 | .21 | 1 |
| Yes | 15/30 | 1.65 | |
| CsA (n = 63; previous treatment) | |||
| No | 22/47 | .07 | 2.84 |
| Yes | 3/16 | 1 | |
| Androgens (n = 63; previous treatment) | |||
| No | 9/25 | .56 | 1 |
| Yes | 16/38 | 1.27 | |
| Recipient sex | |||
| Male | 29/79 | .14 | 1 |
| Female | 13/50 | 1.63 | |
| Donor sex (128) | |||
| Male | 20/70 | .09 | 1 |
| Female | 22/58 | 1.50 | |
| Patient age, y | |||
| Younger than 15 | 11/49 | .04 | 1 |
| 15 or older | 31/80 | 2.04 | |
| Younger than 15 | 11/49 | .17 | 1 |
| 15-20 | 8/22 | 1.85 | |
| 20-30 | 12/34 | 1.87 | |
| Older than 30 years | 11/24 | 2.47 | |
| Patient CMV serologic status (105) | |||
| Negative | 15/43 | .70 | 1.15 |
| Positive | 16/62 | 1 | |
| Major ABO incompatibility | .57 | ||
| No | 38/119 | 1 | |
| Yes | 4/10 | 1.34 | |
| Transfusions before transplantation (109) | |||
| Fewer than 20 | 18/63 | .13 | 1 |
| 20 or more | 18/46 | 1.66 | |
| Interval before transplantation (128) | |||
| Less than a year | 29/107 | .001 | 1 |
| More than a year | 12/21 | 2.96 | |
| Conditioning regimen | |||
| Cy-ATG | 2/31 | .006 | 1 |
| Cy-TAI | 40/98 | 5.81 | |
| GvHD prophylaxis regimen | |||
| MTX alone | 6/16 | .13 | 1 |
| CsA alone | 21/46 | 1.24 | |
| CsA + MTX | 15/67 | 0.64 |